Harbor Capital Advisors Inc. Purchases 11,784 Shares of REGENXBIO Inc. (NASDAQ:RGNX)

Harbor Capital Advisors Inc. increased its position in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 48.5% during the third quarter, HoldingsChannel reports. The fund owned 36,082 shares of the biotechnology company’s stock after buying an additional 11,784 shares during the quarter. Harbor Capital Advisors Inc.’s holdings in REGENXBIO were worth $379,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Allspring Global Investments Holdings LLC acquired a new stake in shares of REGENXBIO during the first quarter valued at about $56,000. nVerses Capital LLC boosted its position in REGENXBIO by 183.3% during the 3rd quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock worth $36,000 after buying an additional 2,200 shares during the period. Headlands Technologies LLC grew its holdings in REGENXBIO by 276.8% during the 1st quarter. Headlands Technologies LLC now owns 3,828 shares of the biotechnology company’s stock worth $81,000 after acquiring an additional 2,812 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in REGENXBIO by 64.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock valued at $100,000 after acquiring an additional 3,720 shares during the period. Finally, Diversified Trust Co acquired a new position in REGENXBIO in the 2nd quarter valued at approximately $121,000. Institutional investors and hedge funds own 88.08% of the company’s stock.

Insider Buying and Selling at REGENXBIO

In other REGENXBIO news, Director Argeris N. Karabelas sold 10,000 shares of the firm’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total value of $101,100.00. Following the transaction, the director now directly owns 11,286 shares of the company’s stock, valued at approximately $114,101.46. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 13.13% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

RGNX has been the topic of several analyst reports. HC Wainwright boosted their price objective on shares of REGENXBIO from $39.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday. Barclays reduced their price target on REGENXBIO from $55.00 to $50.00 and set an “overweight” rating on the stock in a research report on Monday, August 5th. Chardan Capital restated a “buy” rating and set a $52.00 price objective on shares of REGENXBIO in a research report on Tuesday, October 22nd. Raymond James reiterated an “outperform” rating and issued a $18.00 target price on shares of REGENXBIO in a report on Thursday, October 10th. Finally, StockNews.com upgraded shares of REGENXBIO from a “sell” rating to a “hold” rating in a report on Friday, September 20th. Three equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, REGENXBIO currently has an average rating of “Moderate Buy” and an average price target of $35.55.

REGENXBIO Price Performance

RGNX stock opened at $11.19 on Friday. The company’s 50-day moving average is $10.60 and its 200-day moving average is $12.52. The stock has a market capitalization of $553.01 million, a PE ratio of -2.12 and a beta of 1.23. REGENXBIO Inc. has a 1 year low of $8.53 and a 1 year high of $28.80.

REGENXBIO (NASDAQ:RGNX) last released its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($1.16) by ($0.01). REGENXBIO had a negative net margin of 270.74% and a negative return on equity of 68.21%. The firm had revenue of $24.20 million for the quarter, compared to the consensus estimate of $21.35 million. On average, analysts anticipate that REGENXBIO Inc. will post -4.66 earnings per share for the current fiscal year.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.